Diabetic peripheral neuropathy (DPN) is a chronic complication of diabetes, and its exact pathogenesis remains unclear. Autophagy plays an important role in neurodegenerative diseases, ischemiareperfusion injury of nerve tissues, and nerve tissue injury repair. Lipin1 is a phosphatidic acid phosphatase enzyme that converts phosphatidic acid (PA) into diacylglycerol (DAG), a precursor of triacylglycerol and phospholipids which plays an important role in maintaining normal peripheral nerve conduction function. Here, we show that induction of DPN rat model via STZ injection could reduce Lipin1 expression, prevent DAG synthesis, and results in autophagic hyperactivity. Interestingly, these effects increase the apoptosis of Schwann cells and lead to demyelination in sciatic nerve in DPN rats.More importantly, upregulation of lipin1 in the DPN rats ameliorated autophagy disorders and pathological changes of the sciatic nerve, which associated with the increase of the motor nerve conductive velocity (MNCV) in DPN rats. In contrast, lipin1 downregulation exacerbates neuronal abnormalities and facilitates the genesis of DPN phenotypes in rats. In addition, overexpression of lipin1 in RSC96 cells also signi cantly decreased the autophagic hyperactivity and apoptosis induced by hyperglycemia. These results suggest that lipin1 may exert neuroprotection within the sciatic nerve anomalies and may serve as a potential therapeutic target for the treatment of DPN.